CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-20 | Michor Franziska Director | Grant or award · Stock Option (Right to Buy) | +82,781 | 82,781 | ||
| 2024-11-15 | Mauro David J Chief Medical Officer | Shares withheld for taxes | −4,187 | $6.18 | $26K | 225,429 |
| 2024-11-15 | Secora Michael Chief Financial Officer | Shares withheld for taxes | −11,937 | $6.18 | $74K | 1,487,694 |
| 2024-11-15 | Marriott Tina President and COO | Shares withheld for taxes | −14,286 | $6.18 | $88K | 506,852 |
| 2024-11-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −26,023 | $6.18 | $161K | 736,633 |
| 2024-11-14 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-11-14 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.35 | $147K | 762,656 |
| 2024-11-14 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,056,700 | ||
| 2024-11-13 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 782,656 | ||
| 2024-11-13 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.74 | $155K | 762,656 |
| 2024-11-13 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,076,700 | ||
| 2024-11-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,514,631 |
| 2024-11-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $7.66 | $115K | 1,499,631 |
| 2024-11-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 337,635 | ||
| 2024-11-12 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.64 | $87K | 7,066,113 |
| 2024-11-12 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +39,375 | $2.22 | $87K | 1,490,256 |
| 2024-11-12 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −15,000 | $7.64 | $115K | 1,475,256 |
| 2024-11-12 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −39,375 | 377,010 | ||
| 2024-10-29 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $6.72 | $77K | 7,077,560 |
| 2024-10-24 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +6,000 | $1.06 | $6K | 527,138 |
Page 13 of 41 · 805 trades